Insights & Analysis
There’s one constant in healthcare: change. Count on us to break down the trends so you can stay up to date. Follow our take on each piece of this deep, intertwined, and often perplexing industry to find opportunities and practical approaches to move healthcare forward.
Today, Avalere published a technical appendix to the PPVF Version 1.0 methodology report, outlining a quantitative method for incorporating patient preferences into value assessments and healthcare decision making.
As the deadline approaches for providers to make decisions on their participation in BPCI Advanced, Avalere analysis shows that certain conditions may provide greater opportunity for success.
The Department of Health and Human Services is seeking public input on a variety of proposals related to drug costs, providing stakeholders with an unprecedented opportunity to shape the administration's drug pricing policies.
CMS removes 25 existing hospital quality measures in the Proposed FY2019 Inpatient Prospective Payment System (IPPS) Rule as part of its broader effort to focus on measures that matter.
States can pursue various policy opportunities to encourage vaccination and increase access to vaccines.
Avalere's founder and president, Dan Mendelson, recently sat down with Senior Housing News editors to discuss opportunities for senior living providers to leverage data to facilitate synergistic partnerships with payers.
Avalere evaluated payer policies for biologics when biosimilars are available.
Quality measurement in the adult vaccine space has evolved rapidly. Recent advancements continue to propel efforts to drive adult immunization uptake.
On April 24, 2018, Avalere experts were joined by Aledade CEO, Farzad Mostashari, MD, to discuss the latest developments coming out of the Center for Medicare & Medicaid Innovation (CMMI).
The House and Senate are advancing legislative packages aimed at mitigating the crisis.
President Trump is expected to announce a drug pricing plan in the coming weeks; signals from the White House indicate potential alignment around several priority policies.
Avalere examines the effect of foundation-sponsored financial assistance on out-of-pocket costs and federal spending.
MSSP and CMMI demonstrations vary in budgetary impact but generally show quality improvement.
Coordinated information sharing can facilitate the delivery of integrated care to patients using both physical and behavioral health services.
In response to the concern that overprescribing is a driver of the opioid crisis, payers are limiting opioid fills as one solution.
The Centers for Medicare & Medicaid Services released the final Notice of Benefit and Payment Parameters (NBPP) for the 2019 plan year.
In just two years, on March 23, 2020, biologics currently regulated as drugs will transition to being regulated as biologics. Many aspects of how FDA will implement this transition have yet to be established.
Most people are familiar with generic drugs as less costly alternatives to drugs whose patents have expired.
Increasingly, states are taking steps to control prescription drug spending and prices.
On March 6, Avalere experts came together to discuss the latest Medicaid developments.